Voyager Therapeutics
75 Sidney Street
Cambridge
Massachusetts
02139
United States
Tel: 910-509-3977
Website: http://www.voyagertherapeutics.com/
126 articles with Voyager Therapeutics
-
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting kicked off Monday with multiple presentations highlighting the potential of new treatments for a myriad of diseases.
-
Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting
5/16/2022
Voyager Therapeutics, Inc. is scheduled to present findings demonstrating preclinical proof-of-concept for its vectorized anti-HER2 antibody program and cross-species translatability for its novel AAV5-derived capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting.
-
Biogen is bolstering its multiple sclerosis (MS) pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic, MR-004.
-
Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results
5/4/2022
Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus capsids, reported first quarter 2022 financial and operating results.
-
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting
5/3/2022
Voyager Therapeutics, Inc. today announced nine data presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19 in Washington, D.C.
-
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
-
Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
3/22/2022
Voyager Therapeutics, Inc. today announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D., as chief executive officer (CEO).
-
Less than two months after joining the executive committee of the Voyager Therapeutics Board of Directors, Alfred W. Sandrock Jr. has been named CEO of the company.
-
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
3/8/2022
Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus capsids, reported fourth quarter and full year 2021 financial and operating results.
-
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
3/8/2022
Voyager Therapeutics, Inc. announced an agreement through which Novartis may exercise options to license novel AAV capsids generated from Voyager’s RNA-driven TRACERTM capsid discovery platform for potential use with three undisclosed CNS targets and options to access capsids for two additional targets to be agreed on in the future.
-
Voyager has partnered with Novartis for the latter to use the gene therapy company's capsid discovery platform to create new treatments for three undisclosed CNS targets.
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences - Feb 10, 2022
2/10/2022
Voyager Therapeutics, Inc. a gene therapy company developing life-changing treatments and next-generation adeno-associated virus technologies, announced that it will participate in the following virtual investor conferences.
-
BioSpace Movers & Shakers, Feb. 4
2/4/2022
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers. -
Alfred Sandrock Jr., the former head of research and development at Biogen, has taken a position on the board of directors of Cambridge, Mass.-based Voyager Therapeutics.
-
Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee
2/3/2022
Voyager Therapeutics, Inc. announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D. to its Board of Directors, effective February 7, and a newly formed Executive Committee of the Board consisting of Dr. Sandrock, Michael Higgins, interim chief executive officer and Board Chairman, and Glenn Pierce, M.D., Ph.D., interim chief scientific officer and Board member.
-
Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
11/19/2021
Voyager Therapeutics, Inc. today will present preclinical data demonstrating that IV dosing of a proprietary AAV vector identified by the TRACER™️ screening technology, encoding an anti-HER2 antibody payload, prevented tumor growth in models of HER2+ brain metastases.
-
Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
11/16/2021
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced it will present preclinical data from its vectorized antibody program at the 26th Society for Neuro-Oncology (SNO) Annual Meeting on Nov. 19, 2021.
-
Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
11/2/2021
Voyager Therapeutics, Inc. today reported third quarter 2021 financial and operating results.
-
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
10/20/2021
Voyager Therapeutics, Inc. today announced the presentation of preclinical data demonstrating a single intravenous (IV) dose of its novel GBA1 gene replacement therapy
-
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
10/6/2021
Voyager receives $30 million up front with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties